BLOOMINGTON, Ind., – November 8, 2017 – AB BioTechnologies, Inc., a privately-held pharmaceutical contract service provider, announced today that Bryan Hudson and Ben Lisby have joined the company’s executive team as Director of Quality, Validation, and IT, and Director of Operations and Facilities respectively. Hudson brings more than 22 years of industry experience to his new responsibilities of leading quality assurance, quality control, validation, and information technology initiatives. Lisby brings over 18 years of pharmaceutical contract manufacturing experience in both the facilities and process equipment arenas. Lisby is leading the current GMP manufacturing expansion which includes erecting a new state-of-the-art facility in Bloomington, Indiana.
Mr. Hudson joins AB BioTechnologies after having served as a pharma-industry consultant for the last year. Prior to that, he served on the leadership team at BioStorage Technologies for 4 years in separate roles as the Quality Assurance Director and Laboratory Services Director. He began his career in the Quality Control area of Cook Pharmaceutical Solutions/Baxter BioPharma Solutions. He then moved to Sentry BioPharma Services and served as the Quality Assurance and IT Manager for 7 years. Hudson graduated from Purdue University in 1995 with a BS degree in Biochemistry and has completed graduate coursework in the field of Informatics.
“I am excited to be part of the AB BioTechnologies’ team,” said Hudson. “The company is implementing the latest technology in regards to pharmaceutical formulation, filling, and lyophilization equipment. I look forward to applying my past experience and contributing to the future success of the company.”
Mr. Lisby joined AB BioTechnologies in February of this year as Facilities & Operations Manager until his promotion to Director of Operations and Facilities. Lisby started his career with Cook Imaging/Cook Pharmaceutical Solutions and continued with the business after its sale to Baxter Healthcare Corporation. While there, he served in engineering roles that supported packaging, facilities, critical systems, maintenance, automation and aseptic manufacturing. He has managed several multi-million-dollar capital equipment procurement projects. In addition, Lisby has broad experience with facility and process design, implementation and operations in support of critical systems, sterile filling, and finishing.
“It is a true honor to be a part of the dynamic team of talented professionals at AB Biotechnologies,” said Lisby. “It is an exciting period in our growth and I look forward to our bright future and to the tremendous opportunities and successes that lie in store both for our company and for our clients as we expand our capabilities and capacity.”
In this time of rapid transition, AB BioTechnologies relies on dedicated team members like Bryan and Ben. They bring more than four decades of combined experience to our team. Their capable leadership will ensure our expansion is quality from the ground up,” said Dr. Jeff Schwegman, CEO and Founder.
Dr. Schwegman notes that “Bryan has supported our team through several months of rapid growth, providing guidance and expertise. Quality, Validation, and IT are integral to GMP manufacturing and I have confidence that Hudson will lead those departments to success. Ben has led the effort to bring our GMP expansion from paper to real life. His knowledge and experience cover all aspects of Operations and Facilities. I know both of those departments are in good hands with Lisby and Hudson as their directors.
About AB BioTechnologies, Inc.
AB BioTechnologies, Inc. is a contract service provider offering lyophilization, formulation, and process development services for injectable drugs, diagnostics, and tissue products. The company was founded in February 2008 by J. Jeff Schwegman, Ph.D., as a teaching and consulting firm. In early 2010, the first laboratory was opened. Since then, AB BioTechnologies has quickly grown, expanding services and laboratory space, to keep up with client demand. The company is in the process of further expanding their capabilities and services with the construction of a new pharmaceutical contract manufacturing facility, targeted to be on-line in early 2018. The expansion will allow manufacture and testing of injectable drug products for clinical and small-scale commercial use. For more information, visit www.ab-biotech.com.
Office: (812) 287-8493